SecBot SecBot
SECBOTREPLAY Home › Report › ONC

ONC · BeOne Medicines reported Q3 2026 total revenue of $1.89B (+34% YoY) and…

BeOne Medicines Ltd. · 8-K filed Nov 5, 2026 at 06:04 ET

At the news

BULLISHIMPACT 6/10

8-K filed Nov 5, 2026 at 06:04 ET

BeOne Medicines reported Q3 2026 total revenue of $1.89B (+34% YoY) and GAAP diluted EPS of $3.28 (+201% YoY), both well above consensus estimates of $1.76B and $1.88. The company raised its full-year 2026 revenue guidance to $6.9B-$7.0B from $6.6B-$6.8B and lifted GAAP operating income guidance to $1.2B-$1.3B. BRUKINSA global sales reached $1.4B (+34% YoY), driven by U.S. growth of 36%.

  • Total revenue $1.89B, +34% YoY, above $1.76B consensus
  • GAAP diluted EPS $3.28, +201% YoY, above $1.88 consensus
  • Non-GAAP diluted EPS $4.59, +73% YoY
  • BRUKINSA global sales $1.4B, +34% YoY; U.S. sales $1.0B, +36% YoY

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access